Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 9/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25455499 | 0.76 | PDPK1 (0.41) | CHEK2ESR1HDAC4 | |
| SCHEMBL25640339 | 0.76 | HTR3E (0.44) | ESR1NOS1 | |
| SCHEMBL25640319 | 0.76 | HTR3E (0.44) | ESR1NOS1 | |
| SCHEMBL25642448 | 0.74 | NOS1 (0.33) | NOS1 | |
| SCHEMBL23973974 | 0.71 | NOTUM (0.41) | NOS1GPR119 | |
| SCHEMBL25454883 | 0.71 | NOS3 (0.31) | NOS1 | |
| SCHEMBL30463551 | 0.69 | DYRK1A (0.47) | CD38DYRK1ACHEK1CHEK2DYRK2 | |
| SCHEMBL25640352 | 0.69 | VNN1 (0.31) | — | |
| SCHEMBL25640424 | 0.68 | HTR3E (0.50) | ESR1NOS1 | |
| SCHEMBL25454601 | 0.68 | NOS3 (0.46) | NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2024-01-25 | — | — | US | disclosed |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | INSILICO MEDICINE IP LIMITED (HK) | 2023-08-22 | — | — | US | disclosed |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | INSILICO MEDICINE IP LIMITED (HK) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025860-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | CD38 2909/4885DYRK1A 4754/4885CHEK1 543/4885 |
| US-20230192624-A1 | SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | ACE2, ACE, SARS1 | CD38 2909/4885DYRK1A 4754/4885CHEK1 543/4885 |
| US-11731944-B2 | SARS-CoV-2 inhibitors for treating coronavirus infections | ACE2, ACE, SARS1 | CD38 2909/4885DYRK1A 4754/4885CHEK1 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.